Peptide facts, from the official record.

Check whether a peptide is FDA-approved, what has been studied in people, and what changed recently. Every fact links to its source.

FDA-approved
Approval reported abroad
In clinical trials
Not FDA-approved

Recent official changes

Status tracker →
  1. Exenatide

    FDA publishes its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.

  2. Amycretin

    ClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes.

  3. Rusfertide

    DailyMed publishes the Mimrylo label version cited on this page.

  4. Palopegteriparatide

    DailyMed publishes the Yorvipath label version cited on this page.

Official sources last checked November 17, 2026.

How it works: we collect official records from the FDA, DailyMed, ClinicalTrials.gov, PubMed and the Federal Register, check the main sources daily, and cite the source for each fact. Read our methodology.

Researchers and developers: research atlas, evidence map, public data and agent navigation index.